<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00138554</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A2304E1</org_study_id>
    <nct_id>NCT00138554</nct_id>
  </id_info>
  <brief_title>Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes</brief_title>
  <official_title>Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a
      single oral drug. This is a 28-week extension to a study to assess the safety and
      effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels
      when added to pioglitazone in people with type 2 diabetes not at target blood glucose levels
      on pioglitazone or rosiglitazone alone. The purpose of the extension study is to gather data
      on the long-term safety and effectiveness of vildagliptin in people with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of vildagliptin in combination with pioglitazone during 52 weeks of treatment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in HbA1c at 52 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c between 24 weeks and 52 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose at 52 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose between 24 weeks and 52 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HOMA B at 52 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HOMA IR at 52 weeks</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">318</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>vildagliptin 50 mg qd + pioglitazone 45 mg qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vildagliptin 50 mg qd + pioglitazone 45 mg qd for 28 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vildagliptin 50 mg bd+ pioglitazone 45 mg qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vildagliptin 50 mg bd + pioglitazone 45 mg qd for 28 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vildagliptin</intervention_name>
    <arm_group_label>vildagliptin 50 mg qd + pioglitazone 45 mg qd</arm_group_label>
    <arm_group_label>vildagliptin 50 mg bd+ pioglitazone 45 mg qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>pioglitazone 45 mg qd</description>
    <arm_group_label>vildagliptin 50 mg qd + pioglitazone 45 mg qd</arm_group_label>
    <arm_group_label>vildagliptin 50 mg bd+ pioglitazone 45 mg qd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Only patients successfully completing study CLAF237A2304 are eligible

          -  Written informed consent

          -  Ability to comply with all study requirements

        Exclusion Criteria:

          -  Premature discontinuation from study CLAF237A2304

          -  Other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2361</url>
    <description>Results for CLAF237A2304E1 from Novartis Clinical Trials Website</description>
  </link>
  <results_reference>
    <citation>Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab. 2010 Jun;12(6):495-509. doi: 10.1111/j.1463-1326.2010.01214.x.</citation>
    <PMID>20518805</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2005</study_first_submitted>
  <study_first_submitted_qc>August 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>vildagliptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

